RETATRUTIDE

Description

Exciting Research Findings:

Body Weight Reduction
This New England Journal of Medicine study showed that weekly retatrutide doses up to 12mg led to an average 24.2% body weight reduction over 48 weeks in adults with obesity, with all participants in higher-dose groups achieving at least 5% weight loss.

Improved Glycemic Control
Published in The Lancet, this trial demonstrated that retatrutide doses up to 12mg improved glycemic control (reducing HbAlc by up to 2.02%) and achieved dose-dependent weight loss of up to 16.94% over 36 weeks in adults with type 2 diabetes, with a safety profile similar to other GLP-1 agonists.

Reduced Liver Fat
This Nature Medicine trial found that retatrutide reduced liver fat by up to 82% over 48 weeks in participants with obesity and liver disease, alongside improvements in insulin sensitivity and metabolic markers, supporting its role in addressing obesity-related complications.